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Abstract: Even though conventional botulinum neurotoxin (BoNT) products have shown 
successful treatment results in patients with benign blepharospasm (BEB), the main,   potential 
long-term side effect of BoNT use is the development of immunologic resistance due to the 
production of neutralizing antibody to the neurotoxin after repeated injections. Xeomin® 
(incobotulinumtoxinA), a unique botulinum neurotoxin type A (BoNT/A) drug free of   complexing 
proteins otherwise contained in all conventional BoNT/A drugs, was recently approved by 
US Food and Drug Administration for the treatment of cervical dystonia or blepharospasm in 
adults. The newly approved BoNT/A drug may overcome this limitation of previous conven-
tional   products, since it contains pure neurotoxin (150 kDa) through a manufacturing process 
that separates it from complexing proteins such as hemagglutinins produced by fermentation of 
Clostridium botulinum. Many studies have also shown that Xeomin® has the same efficacy and 
safety profile as complexing protein-containing products such as Botox® and is exchangeable with 
Botox® using a simple 1:1 conversion ratio. Xeomin® represents a new treatment option for the 
repeated treatment of patients with blepharospasm in that it may reduce antibody-induced therapy 
failure. But, long-term comparative trials in naïve patients between Xeomin® and conventional 
BoNT/A drugs are required to confirm the low   immunogenicity of Xeomin®.
Keywords: blepharospasm, botulinum neurotoxin type A, Xeomin®, incobotulinumtoxinA, 
complexing proteins, neutralizing antibodies
Introduction
Blepharospasm is a localized form of dystonia consisting of involuntary tonic and 
spasmodic contractions of the orbicularis oculi, corrugator supercilii, and procerus 
muscles, leading to partial or complete closure of the eyelids. These contractions may 
be intense and last from several seconds to a few minutes.1
It is a bilateral condition with tonic rather than clonic spasms, which develops typi-
cally between 50 and 70 years of age. Women appear to be more affected than men. 
The exact cause remains unknown, but may result from damage to areas of the basal 
ganglia including the superior colliculus, pars reticularis of the substantia nigra, and 
nucleus raphe magnus. The most common form is called benign essential blepharos-
pasm (BEB), which is limited to the orbitopalpebral area.1 Botulinum toxin (BoNT) 
injections were first used to treat strabismus in 1977 by Alan Scott, a pediatric 
ophthalmologist,2 and subsequently used to treat blepharospasm in the early 1980s 
by Frueh et al3 and Scott et al.4 BoNT is highly effective and well tolerated in the 
symptomatic treatment of a very broad range of conditions involving either muscle 
hyperactivity such as blepharospasm or cervical dystonia, or cholinergic hyperactivity Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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such as hyperhidrosis or hypersalivation.5,6 Recently, BoNT 
has been approved for the treatment of glabellar rhytids and 
migraine headaches.7
BoNTs act on the peripheral nervous system where 
they inhibit acetylcholine exocytosis at the motor endplate 
within the neuromuscular junction by inhibition of prote-
olytic cleavage of different proteins of the acetylcholine 
transport protein cascade (soluble N-ethylmaleimide-
sensitive fusion attachment protein receptor (SNARE) 
proteins). Botulinum toxin type A (BoNT/A) hydrolyses 
SNAP-25 (synaptosomal-associated protein 25) which is 
located on the presynaptic cell membrane whereas type 
B (BoNT/B) acts on synaptobrevin or VAMP (vesicle-
associated membrane protein) which is embedded in 
the acetylcholine vesicle membrane. By cleaving these 
target proteins, BoNT prevents the fusion of the synaptic 
vesicle with the presynaptic membrane, thereby blocking 
the release of acetylcholine in the synaptic cleft. Between 
a heavy chain (100 kDa) and a light chain (50 kDa) of 
neurotoxin, only the light chain is responsible for the 
pharmacological action of BoNT.1,8
The various strains of the anaerobic bacterium Clostridium 
botulinum produce 7 distinct serotypes of botulinum toxin, of 
which 5 are pharmacologically active in man (A, B, E, F, and 
G) and 2 are inactive (C and D).9 Today, 2 serotypes are used 
in therapeutics, botulinum toxin type A and type B.
In August, 2010 the US Food and Drug Administra-
tion (FDA) approved Xeomin® (incobotulinumtoxinA10; 
Merz Pharmaceuticals GmbH, Frankfurt, Germany) for the 
treatment of cervical dystonia or blepharospasm in adults 
(Figure 1). Now Xeomin® is the fourth BoNT product licensed 
for the US market, following Botox® (onabotulinumtoxinA; 
Allergan Inc, Irvine, CA), Dysport® (abobotulinumtoxinA; 
Ipsen Ltd, Slough, Berks, UK), and Myobloc® (rimabotuli-
numtoxinB; Solstice Neurosciences Inc, Malvern, PA).11 With 
this recent entry, 3 type A and 1 type B brands of botulinum 
neurotoxins are available in the US10 (Table 1).
The main long-term side effect of BoNT use is the 
  development of an immunologic resistance due to the produc-
tion of neutralizing antibody for the neurotoxin after repeated 
injections. The frequency of this sensitization reported by 
several authors is around 3% to 10%.12 The newly approved 
BoNT/A drug may overcome this limitation of the other 3 
previous products, since Xeomin® contains only the pure 
neurotoxin (150 kDa) through a manufacturing process that 
separates it from complexing proteins such as hemagglutinins 
(HA) and other proteins in the neurotoxin complex produced 
by fermentation of C. botulinum.11
Xeomin®; BoNT/A preparation free 
of complexing proteins
Xeomin® was first introduced in Germany in July, 2005.13,14 
It received approval for the treatment of blepharospasm 
and cervical dystonia in a number of European countries, 
and then Argentina and Canada, for the treatment of 
blepharospasm, cervical dystonia, and poststroke upper-
limb spasticity,15 and now in the US for cervical dystonia 
and blepharospasm. The FDA’s approval of Xeomin® 
for the treatment of blepharospasm restricts the drug to 
adult patients previously treated with Botox®. Therapy 
with the newer BoNT/A product should be based on the 
previous dose, number, and location of Botox® injections. 
Regardless of whether the patient has cervical dystonia 
or blepharospasm, the treatment sessions should occur no 
more frequently than every 12 weeks. Xeomin® is supplied 
in single-use vials containing 50 or 100 units of lyophilized 
incobotulinumtoxinA, which do not require refrigeration 
before use.11
In all naturally occurring serotypes of botulinum toxin 
(types A–G), the active neurotoxin (150 kDa; 100 kDa of a 
heavy chain and 50 kDa of a light chain) is noncovalently 
associated with a set of nontoxic and inactive complexing 
proteins (hemagglutinins [HA] and non-hemagglutinins 
[NHA]) and thus forms high molecular toxin complexes.6,16–18 
The molecular weight of the toxin complex ranges between 
230 and 900 kDa, depending on the serotype.1 All previous 
BoNT drugs, including Botox® and Dysport®, contain these 
nontoxic and inactive complexing proteins in addition to 
the neurotoxin (Figure 2).6 This new preparation, Xeomin®, 
is derived from a wild-type strain of C. botulinum type A 
Figure  1  Recently  US  FDA  approved  botulinum  toxin  type  A,  Xeomin® 
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(ATCC 3502) which is the same strain from which Botox® is 
derived and thus has similar biologic activity to Botox®.17,19 
Unlike Botox® it contains only the active neurotoxin moiety 
with complexing proteins removed through a manufacturing 
process for removal all clostridial contaminants.6,11
Clinical functions of complexing 
proteins
The function of the nontoxic portions of the protein 
  complexes in BoNT/A preparations has been studied. It 
was initially thought that these proteins protected the native 
neurotoxin from destruction in the gastrointestinal tract 
with oral ingestion (its natural route of entry).18,20 This was 
subsequently confirmed in biochemical analyses (protease 
resistance) of different toxin serotypes.21 Others have sug-
gested that complexing proteins may have a role in the uptake 
and transcytosis of botulinum toxin through the intestinal 
epithelium to reach and affect muscle.22–24 Xeomin® does not 
have complexing proteins to protect it from the low pH and 
gastric enzymes and therefore shows poor oral bioavailabil-
ity and toxicity.25 However, in the therapeutic setting these 
proteins are not relevant to clinical efficacy.
Another consideration is that complexing proteins may 
in fact limit botulinum toxin diffusion from the injection site 
and thereby minimize adverse events, due to the large size of 
the toxin complex.26–28 The smaller size of Xeomin® might 
more rapidly and easily diffuse away from the target tissue 
into adjacent tissues and produce an adverse effect profile 
different from other BoNT/A drugs. However, an in vivo 
study using Botox®, Dysport®, and a purified preparation of 
BoNT/A (150 kDa) showed that diffusion from the injection 
site does not differ between the 3 preparations.29 Another 
study using 125I-radiolabeled botulinum toxin type A showed 
no difference in the diffusion of the free or complexed form 
of BoNT/A after injection into the muscle, even when using 
high doses.30 Comparing the adverse effect profiles of conven-
tional BoNT/A drugs and complexing protein-free BoNT/A 
drug, indeed, did not reveal any of those differences.5,13,14,31,32 
These findings can be explained by a dissociation of the 
complex consisting of neurotoxin and complexing proteins 
immediately after injection.33 At physiologic pH values, the 
active 150 kDa neurotoxin is efficiently released in less than 
1 minute from the 900 kDa complex.34 This is in contrast 
with the onset time of its therapeutic effect, which is mea-
Table 1 Properties of different botulinum toxin preparations
Brand name Botox® Dysport® Xeomin® Myobloc®/Neurobloc®a
Generic name OnabotulinumtoxinA AbobotulinumtoxinA IncobotulinumtoxinA RimabotulinumtoxinB
Manufacturer Allergan inc 
(USA)
ipsen Ltd 
(UK)
Merz Pharmaceuticals GmbH 
(Germany)
Solstice Neurosciences inc 
(USA)
Serotype A A A B
Target SNARe SNAP-25 SNAP-25 SNAP-25 vAMP (synaptobrevin)
Packaging (units/vial) 100 500 50, 100 2500 (0.5 mL), 5000 (1 mL),   
10,000 (2 mL)
Pharmaceutical preparation Powder Powder Powder Ready-to-use solution 
(5000 U/mL)
Stabilization vacuum drying Freeze drying vacuum drying pH reduction
Complex size (kDa) 900 300–900 150 700
Complexing proteins O O X O
excipients (per vial) HSA 500 ug 
NaCl 900 ug
HSA 125 ug 
Lactose 2500 ug
100 units/vial 
HSA 1 mg 
Sucrose (saccharose)  
4.7 mg
HSA 0.5 mg/mL disodium 
succinate 0.01 M 
NaCl 0.1 M 
H2O 
Hydrochloric acid
Biological activity in relation  
to Botox®
1 1/3 1 1/40
Specific activity (units/ng) 20 40 167 75–125
Storage of packaged product 2°C–8°C 2°C–8°C Room temperature 2°C–8°C
Shelf life 36 months 24 months 36–48 months 24 months
pH of reconstituted preparation 7.4 7.4 7.4 5.6
Storage once reconstituted 2°C–8°C for  
24 hours
2°C–8°C for several 
Hours → 4 hours if stored  
at room temperature
2°C–8°C for 24 hours For a few hours
Notes: aMyobloc® is the brand name in Canada, the United States, and Korea. Neurobloc® is the brand name in the european Union, Norway, and iceland.
Abbreviations: HSA, human serum albumin; VAMP, veslcle associated membrane protein.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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sured in days. Therefore, complexing proteins do not seem 
to be essential for either the stability of the 900 kDa toxin 
complex at physiologic pH or for limiting diffusion of the 
150 kDa neurotoxin after injection of conventional BoNT/A 
preparation.19
Another possible function of complexing proteins in 
a therapeutic setting could be to enhance the stability of 
the botulinum toxin drug during storage before use. How-
ever, a series of stability studies (stress experiments) of 
Xeomin® do not support this hypothesis. The stability of 
Xeomin® was evaluated in both long-term storage studies 
and in short-term temperature-stress studies. The studies 
evaluated the active ingredient (neurotoxin) and inactive 
ingredients (sucrose and human serum albumin [HSA]) of 
vials containing Xeomin® stored at 5°C or 25°C, as well 
as the biologic activity of the neurotoxin (mouse median 
lethal dose [LD50]). After 48 months of storage in a refrig-
erator (5°C) or at room temperature (25°C), no significant 
changes in neurotoxin, sucrose, or HSA content or, more 
importantly, biologic activity, were observed in the Xeomin®. 
Furthermore, storage studies showed that Xeomin® was stable 
for at least 18 months at 30°C and for at least 6 months at 
40°C. Also in short-term temperature-stress studies, there 
was neither loss of activity nor degradation detectable after 
30 days at 60°C. Even at 80°C, the reduction of biologic 
activity occurred within 5 days, although proteolytic activ-
ity had not fallen to below one-third of the initial value after 
10 days, with a decline over time considerably slower than 
for biologic activity.35 Overall, these results demonstrate that 
  complexing proteins are not required to maintain the stability 
of BoNT/A preparations during storage.19 The manufacturer 
reports that Xeomin® is stable at room temperature for 
3 years and new data demonstrate stability for 4 years at 
room temperature.11,36
Complexing proteins may have the disadvantage of 
immunostimulation, since HA, which belong to the com-
plexing proteins, are lectins known as potent stimulators 
of immune cells.11 Lee et al37 reported vaccination experi-
ments in mice with formalin-treated botulinum toxin type B 
(toxoid). The amount of neutralizing antibodies increased 
when the neurotoxoid was complexed with HA, compared 
with the neurotoxoid complexed with NHA, or when the 
neurotoxoid was administered alone. Further analysis showed 
that among the 4 subcomponents of HA designated HA1, 
HA2, HA3a, and HA3b, HA1 and HA3b subcomponents of 
HA accounted for the adjuvant activity. The mechanism of 
increased immune response to HA1 and HA3b appeared to be 
mediated by an increase in interleukin-6, leading to increase 
in CD19+ cells. Further experiments showed that in vitro 
enzyme-linked immunosorbent assay analysis of antibody 
binding to BoNT/A large toxin complex showed that HA1 
was responsible for most of the immunogenic response.37 
Some have commented that this study was flawed and does 
not reflect a therapeutic situation. The dose of toxin used was 
about 1000 times greater than in typical clinical use. The 
antigen immunized into the mice was actually inactivated 
toxin (toxoid) that was treated with formaldehyde, which in 
itself causes the molecule to be more antigenic than native 
proteins.38 However, these and other data confirmed that HA1 
and HA3b appear to increase the immunogenic potential.37
Hence the presence of complexing proteins in com-
mercially available BoNT/A preparations may facilitate an 
immunogenic reaction and the development of neutralizing 
antibodies against the active neurotoxin leading to partial 
or complete clinical unresponsiveness (treatment failure) 
to BoNT/A.19 Indeed, incidence of antibody development 
following treatment with Botox® had been significantly 
reduced since its original formulation was changed to 
reduce complexing proteins and inactive neurotoxin.39,40 
  Furthermore, removing the complexing proteins in the 
manufacture of Xeomin® may reduce this risk markedly. 
Preliminary experiments with Xeomin® also suggest that 
the absence of complexing proteins is indeed associated 
with reduced immunogenicity. In a preclinical animal study 
with Cynomolgus monkeys, repeated injections with 4, 8, 
or 16 U/kg Xeomin® or control were not associated with 
the development of neutralizing antibodies in each group, 
despite clear evidence of biologic activity of the neurotoxin, 
particularly in the highest-dose group.41 The immunogenicity 
of Xeomin® was compared with that of Botox® and Dysport® 
in New Zealand white rabbits. After repeated injection, 
Xeomin® did not induce the formation of neutralizing anti-
bodies, unlike the other preparations.42
Similar results were shown in a human study of up to 
89 weeks in patients with upper limb spasticity who received 
Botulinum toxin (BoNT) preparation
Botulinum toxin (BoNT)
Neurotoxin Non-toxic proteins
(Complexing proteins)
Light chain Heavy chain HA NHA
Excipients
Figure 2 Contents of botulinum toxin preparation.
Abbreviations: HA, Hemagglutinin; NHA, Non-Hemagglutinin.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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multiple injections of Xeomin®; no patient developed 
neutralizing antibodies throughout the study.43 Although in 
the clinical development program of Xeomin® in the US, 
12 of 1080 subjects developed antibodies against the neu-
rotoxin, each of these patients was previously treated with a 
conventional BoNT/A product which contained complexing 
proteins. They may have already been primed by the previ-
ous treatment.44
Several risk factors of this sensitization have been 
identified:12,45 injection of over 100 units of Botox® or 
300 units of Dysport® per session, interval of less than 
3 months between 2 injections, ‘Booster’ technique where 
another dose is injected 2 to 3 weeks after the first injection, 
and use of a BoNT drug with a low intrinsic activity. Cumula-
tive dose, treatment time, and patient age have been excluded 
as risk factors. Antibody-induced therapy failure usually 
develops within the first 2 to 3 years of BoNT therapy.46
Among the above risk factors, the intrinsic activity of 
BoNT drugs is defined as the number of toxin units per the 
amount (nanogram) of clostridial proteins (ie, toxin com-
plex). At each injection of toxin, the administered protein 
mass will be greater when using a toxin with a low intrinsic 
activity. The toxin’s antigenic potential is probably related 
to the total protein concentration injected (protein load), 
and according to Borodic et al,47 this may be a much more 
relevant parameter in the development of a resistance than 
the number of units.
Indeed, in patients with cervical dystonia, the original 
formulation of Botox® (100 U/25 ng protein) was 6 times 
more likely to elicit the production of neutralizing antibodies 
than the newer formulation of Botox® (100 U/5 ng protein) 
which contains fewer complexing proteins and reduced inac-
tive neurotoxin. The authors conclude that the low risk of 
antibody formation after newer Botox® treatment is related 
to lower protein load.39
Xeomin® contains only 0.6 ng of clostridial proteins per 
vial (100 U/0.6 ng protein), whereas the other products con-
tain much more protein: 55 ng in Myobloc®, 5 ng in Botox® 
(100 U/5 ng protein), and 12.5 ng in Dysport® (500 U/12.5 ng 
protein).11
Based on a conversion factor of 1 Botox® or Xeomin® unit 
to 3 Dysport® units,6,48–50 100 units of Botox® or Xeomin® 
are bioequivalent to 300 units of Dysport®. If this same 
equivalent dose of the preparations is injected, in the case of 
Xeomin®, the patient is treated with 0.6 ng of clostridial pro-
tein (neurotoxin alone). In contrast, when treated with Botox® 
or Dysport®, the patient receives a much higher amount of 
clostridial proteins including complexing proteins, 5 ng or 
7.5 ng respectively (Figure 3). In other words, Xeomin® 
contains the lowest amount of BoNT/A with respect to units. 
Thus it has the highest specific potency, and with Xeomin® 
the patients gets the lowest amount of foreign protein,11 
so that the risk of development of any immunogenicity may 
be reduced.
But long-term, trials in naïve patients comparing Xeomin® 
with conventional BoNT/A drugs are required to confirm the 
low immunogenicity of Xeomin®.
Efficacy and safety profile  
of Xeomin®
Based on the fact that Xeomin® is obtained from the same 
strain of C. botulinum as Botox® and on preclinical stud-
ies, the manufacturer first assumed Xeomin® had the same 
potency as Botox®. Subsequently, the registration studies 
using a cross-over design were based on identical potency 
labeling. The result of equivalent experiments in which LD50 
of 5 different batches of Xeomin® and Botox® was compared 
in a blinded fashion demonstrates that there was no differ-
ence in the potency between the 2 preparations.51 Results 
from both registration studies13,14 together with subsequent 
head-to-head potency testing using a mouse lethality (LD50) 
assay17 confirmed the equivalence rate between Xeomin® and 
Botox®. The conclusion of a focal dystonia study also showed 
that Xeomin® had the same efficacy as Botox®, which means 
that 1 unit of Xeomin® is equipotent to 1 unit of Botox®.6 
Dressler50 further confirmed the identical potency labeling by 
his study converting Botox® in a blinded fashion to Xeomin® 
using a 1:1 conversion ratio. Therefore, clinically Xeomin® 
0
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Figure 3 Amount of clostridial protein (blue) of neurotoxin (red) applied in the 
treatment of benign essential blepharospasm (BEB). Dose 100 units of Xeomin® or 
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and Botox® can be exchanged easily using a straightforward 
1:1 conversion ratio.50
The efficacy and safety of Xeomin® in the treatment of 
blepharospasm has been confirmed by a prospective, double-
blind, placebo-controlled, randomized, multicenter study.31,32 
In this study involving 109 patients (mean total dose of 
Xeomin® per treatment visit was 64.8 units), the Jankovic 
Rating Scale (JRS) severity score was significantly reduced 
compared with placebo (P , 0.001). And the most commonly 
reported adverse effects related to Xeomin® vs placebo were 
eyelid ptosis (18.9 vs 8.8%) and dry eye (16.2 vs 11.8%).
Several large clinical studies to compare the efficacy of 
Botox® and Xeomin® have been reported. In comparative 
clinical trials, the efficacy and tolerability of Xeomin® were 
noninferior to that of conventional BoNT/A drugs.13,14 The 
efficacy of Xeomin® was compared with that of Botox® in a 
16-week randomized, double-blind, noninferiority trial in 463 
patients with cervical dystonia. Both treatments significantly 
improved the Toronto Western Spasmodic Torticollis Rating 
Scale severity score compared with baseline, and noninferior-
ity of Xeomin® vs Botox® was demonstrated.14 Similarly, a 
randomized, double-blind study of Xeomin® and Botox® in 
300 patients with blepharospasm found that both treatments 
significantly reduced JRS score from baseline, indicating 
noninferiority of Xeomin®.5,13 There was also no difference 
in the time course of the 2 treatments demonstrated in the 
Kaplan–Meier plot. There were no clinically relevant differ-
ences between Xeomin® and Botox® in safety parameters, 
40 of 148 patients (27.0%) treated with Xeomin® reporting 
adverse events vs 45 of 155 patients (29.0%) treated with 
Botox®. The most common adverse event was ptosis (6.1% 
Xeomin® and 4.5% Botox®).5
In conclusion, the clinical evidence to date suggests that 
Xeomin® is an effective treatment for blepharospasm, which 
does not differ from Botox® in terms of its potency, duration 
of effect, or adverse reaction profile.5 The same efficacy and 
safety profiles could be explained by the immediate dissocia-
tion, which would lead to the generation of the same active 
agent, ie, the 150 kDa active neurotoxin, eliciting the same 
diffusion characteristics and therapeutic effects.
Dosing of Xeomin® should be based on previous Botox® 
treatment. If the previous information is not available, the 
recommended starting dose is 2.5 to 5.0 units per each 
injection site in blepharospasm.52 There is some evidence of 
a dose–response relationship for efficacy and its duration, 
in which the greatest benefits for Xeomin® were observed 
with the highest dose, and Dressler50 reported his experience 
of off-label indications and maximum therapeutic dose up 
to 840 units of Xeomin® as well as Botox® in a variety of 
muscle hyperactivity disorders without producing clinically 
detectable systemic adverse effects. However, few patients 
with blepharospasm received a total dose of greater than 75 
units in the controlled trials and less than 70 units (35 U/eye) 
is recommended for initial total dose so far.52
Based on stability data, Xeomin® is the only preparation 
that remains active for up to 3 or 4 years at room temperature 
before reconstitution. In contrast, other botulinum toxin prod-
ucts require refrigerated storage.19,36,53,54 After reconstitution, 
Xeomin® should be stored for only 24 hours at 4°C, because 
otherwise sterility problems, such as bacterial contamination, 
could occur.11
Conclusion
Xeomin® was originally developed to reduce drug antigenicity, 
which can lead to partial or complete treatment failure. It 
recently became the fourth FDA-approved botulinum toxin drug 
in the US. A lack of complexing proteins differentiates Xeomin® 
from the other BoNT preparations. Many studies have also 
shown that Xeomin® has the same efficacy and safety profile as 
complexing protein-containing products such as Botox® and is 
exchangeable with Botox® using a simple 1:1 conversion ratio. 
Xeomin® represents a new treatment option for the repeated 
treatment of patients with blepharospasm in that it may reduce 
antibody-induced therapy failure. But, long-term, trials in naïve 
patients comparing Xeomin® with conventional BoNT/A drugs 
are required to confirm the low immunogenicity of Xeomin®.
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